Search:

Home Index Back issues Contact

This item requires a subscription.

What’s in the asthma pipeline over the next ten years?
RDIP, Volume 19, Number 1.

It has proved extraordinarily difficult to develop new classes of drug for the treatment of asthma and most new treatments have been improvements of existing classes of drugs, such as corticosteroids and b2-agonists. Furthermore, existing treatments for asthma are highly effective if used correctly, so that there is little room for improvement in the management of the majority of patients. However, several new treatments are currently in development for asthma therapy.1

To view this item, select one of the options below:

Purchase access

In order to view articles you will need to pay a subscription for 24-hour access. You can view all articles on this site during the subscription period.
Please click here to subscribe.
 

Sign in

If you are already have a subscription, please sign in here.

email address

Password

Forgotten your password?

Important

All the articles are in PDF format.

To view the articles you will need Adobe Acrobat Reader.

To download a copy, free of charge,
please click here.

 
Help
  If you need help accessing this site, please click here.

 


The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Respiratory Disease in Practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk